Gene Therapy Specialist Secures £6.5M
- On March 29, 2019
- By GrowthInvest Admin
An Oxford business which specialises in technologies for drug and gene therapy development has secured £6.5m as part of a syndicated funding round.
The cash injection values Oxford Genetics, which is based at Oxford Science Park, at £30.5m.
The funding was provided by Canaccord Genuity, Invesco Asset Management and Mercia.
Ryan Cawood, founder and chief executive of Oxford Genetics, said: “This significant investment round will enable Oxford Genetics to further secure its market-leading position in the expanding fields of CRISPR, gene therapy and antibody engineering.
GET IN TOUCH!
CALL US020 7071 3945
FOLLOW US ON
Throughout our site you will find links to external websites. Although we make every effort to ensure these links are accurate, up to date and relevant, we cannot take responsibility for pages maintained by external providers.